Additional Relevant Details Preliminary results from 18 pediatric patients with primary immune-deficiencies (PIDs) treated at Dr. Locatelli’s site, show continued encouraging results at a median 13 months of follow-up and that all of these patients have remained disease-free with no treatment-related mortality following a T-depleted haploidentical hematopoietic stem cell transplant and infusion of BPX-501.
Initial results from 11 of the 18 patients were included in an oral presentation that took place at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation in April 2016, and the Company is planning to present a comprehensive update on the BP-004 clinical trial in conjunction with the upcoming 58th annual meeting of the American Society of Hematology scheduled to take place December 3-6, 2016 in San Diego, CA.